retatrutide type 2 diabetes trial nct ESC 2024: improves lipid and cardiovascular risk profile in Phase II Retatrutide: The New Triple-Agonist Weight

Brain-Derived Neurotrophic Factor in Fibromyalgia: A Systematic Review and Meta-Analysis of Its Role as a Potential Biomarker

HbA 1c was reduced in SURPASS 15, using from 5 to 15 mg of TZP per week, by between 1.69 to 2.58%, and a new plateau of HbA 1c and fasting serum glucose (FSG) was reached with approximately 2430 weeks of treatment

GLP-1 and the drugs that mimic it help slow the movement of food through the stomach, a process called gastric emptying, which supports both blood sugar control and weight loss

If you missed the other articles in the series, you can read them here: Part 1: How do GLP-1 medications like Wegovy, Ozempic, and Mounjaro work